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Atef Salam, MD, Thomas F. Dodson, MD, Elliott L. Chaikof, MD, PhD, and
Ravi Kumar Veeraswamy, MD, Atlanta, Ga
Objective: This study evaluated the durability of adjunctive endovascular neck procedures, including aortic cuffs, Palmaz
stents (Cordis, Miami Lakes, Fla), and high-pressure balloon angioplasty, at managing intraoperative proximal neck
complications during endovascular aortic aneurysm repair (EVAR).
Methods: This was a single-center retrospective review of EVARs. The primary outcome variable studied was survival free
of a graft-related event (GRE). GRE was defined by the occurrence of one of the following: type I endoleak, sac
enlargement, aneurysm rupture, death, or procedure related to the aortic neck. These outcome variables were assessed
relative to the preoperative anatomic neck variables (neck length, diameter, degree of angulation, degree of circumfer-
ential thrombus, and presence of conicity), procedural variables (manufacturing type of graft, use of a Palmaz stent), and
patient characteristics (age and presence of medical comorbidities). Outcomes were assessed by t tests, Pearson 2, and
Kaplan-Meier analysis, when appropriate.
Results: A total of 174 EVARs performed between January 2005 and December 2007 were evaluated. Fifty-six adjunctive
procedures were performed, with a 97% primary-assisted exclusion rate. Patients who received an adjunctive therapy had
similar freedom from a GRE compared with EVARs that did not require adjunctive therapy (35.5  2.6 vs 34.8  1.5
months, P .31, log-rank test). Subset analysis identified a significant association between Palmaz stent placement at the
time of EVAR and decreased freedom from GREs (hazard ratio, 2.87; 95% confidence interval, 1.21-6.77; P  .02).
Conclusions:Midterm results suggest that adjunctive therapies to manage intraoperative proximal neck complications do
not compromise durability. The subset of patients requiring aortic neck Palmaz stent placement at the time of EVAR are
among those at highest risk for subsequent GRE. (J Vasc Surg 2010;52:1435-41.)One of the main anatomic factors precluding an endo-
vascular repair of an infrarenal aortic aneurysm (EVAR) is
unfavorable aortic neck morphology, also referred to as a
hostile neck.1 Increasingly, patients with hostile necks2
who are deemed high risk for open aneurysm repair are
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which is associated with an increased risk of proximal type I
endoleak or aneurysm rupture after repair, or both, due to
anatomic limitations.3 Adjunctive therapies are often re-
quired to manage intraoperative type I endoleaks.1,3-7
Common adjunctive therapies include variable combina-
tions of proximal aortic cuff placement, high-pressure bal-
loon angioplasty, and balloon-expandable metallic stent
placement such as the Palmaz stent (Cordis, Miami Lakes,
Fla).1,4-7 These adjunctive procedures have been used with
excellent initial technical success.1,4-7
Despite their increasing use, the durability of EVAR in
patients who require adjunctive therapeutic measures at the
time of primary repair is unclear. Some authors cite a lower
freedom from aneurysm-related death when adjunctive
therapies are used, while others argue that these therapies
do not alter the long-term durability of EVARs.5,8 More-
over, the risk factors for the development of late graft-
related complications for patients treated with adjunctive
procedures have not been well defined.5-8 Current evi-
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EVAR in patients with hostile neck anatomy.1
The present study evaluated the safety and durability of
adjunctive interventions used to treat intraoperative proxi-
mal type I endoleaks. We evaluated the durability of aneu-
rysm exclusion by testing the hypothesis that EVARs re-
quiring adjunctive procedures, including Palmaz stents,
aortic cuffs, or high-pressure angioplasty, had higher rates
of late failure relative to those repaired without adjunc-
tive procedures. The primary outcome studied was free-
dom from any adverse graft-related event (GRE). Sec-
ondary analyses explored relationships between GRE and
individual hostile neck anatomic variables of neck length,
conical neck shape, neck diameter, neck angulation, and
neck thrombus; specific adjunctive procedures at the
time of EVAR, including intraoperative Palmaz stent
placement and suprarenal fixation device; and patient
comorbidities.
MATERIALS AND METHODS
This was a single-center retrospective review of elective,
infrarenal EVAR procedures performed between January
2005 and October 2007 at Emory University Hospital by
the Department of Vascular Surgery and Endovascular
Therapy. The study excluded patients presenting with
symptomatic aneurysms, ruptured or leaking aneurysms,
mycotic aneurysms, isolated common iliac artery aneu-
rysms, or pseudoaneurysms from prior open aortic proce-
dures. Also excluded were patients who required concom-
itant debranching procedures. No patients had a history of
a prior aortic stent graft. Patients were excluded from the
analysis if preoperative imaging data were unavailable for
review. Patients were identified from an operative registry,
and additional data were collected from electronic medical
records and archived images. Institutional Review Board
approval was obtained before data collection and analysis.
End points and study design. The patients were
placed into two groups: aortic necks treated with adjunctive
procedures and aortic necks not treated with adjunctive
procedures (Fig 1). The primary outcome measured was
the freedom from any GRE, defined as survival without
aneurysm-related morbidity (limb thromboses, migration,
aneurysm enlargement, delayed type I endoleak, or rup-
ture), aneurysm-related procedures (repeat intervention for
adjunctive aortic neck procedures, conversion to open re-
pair), or aneurysm-related death. Outcomes not included
in this end point were type II, III, or IV endoleaks, or
procedures related to the treatment of such complications.
After assessing the durability of adjunctive procedures
in endovascular repairs, we sought to secondarily assess risk
factors for midterm failure at the proximal neck. Specifi-
cally, we assessed the effect of the individual neck variables
(neck length, neck angulation, neck conicity, percentage
of circumferential neck thrombus, and neck diameter), pa-
tient comorbidities, and intraoperative technical variables
(Palmaz stent placement, suprarenal device fixation, and
use of aortic cuffs) on freedom from GRE.Imaging and anatomic variables. All patients under-
went computed tomography (CT) angiography before en-
dograft implantation. All radiographs were reviewed retro-
spectively by a single observer (J.C.) who was blinded to
periprocedural or long-term outcomes. Measurements of
20 randomly selected radiographs were performed by an
attending vascular surgeon (R.V.). There was no interob-
server variability noted in the measurements of these ran-
domly selected radiographs. Typically, noncontrast, con-
trast, and delayed images were obtained at 1.25- to 3.0-mm
slices, with the subsequent creation of 3-dimensional (3D)
reconstructions. Electronic calipers available on the view-
ing stations were used to measure aneurysmal diameter and
the following aortic neck variables as previously de-
scribed4,5,9-13:
1. Neck length—the distance from the most caudal renal
artery and the onset of the aneurysm (15% increase in
aortic diameter).
2. Neck diameter—the distance between the outer walls
along the minor axis at the midpoint of the aortic neck.
3. Aortic neck angulation—the angle between the flow axis
of the infrarenal neck (line running from the beginning
and end of the aortic neck) and the flow-axis of the
aneurysm (line running from the onset of the aneurysm
to the aortic bifurcation). The neck angulation for pa-
tients who did not have CT scans with 3D reconstruc-
tions was calculated retrospectively from the intraoper-
Fig 1. Study design shows the outcome of 242 patients undergo-
ing endovascular aneurysm repair (EVAR).ative or preoperative aortogram.
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Volume 52, Number 6 Chung et al 14374. Neck thrombus—the percentage of the circumference
of the aortic neck that was covered by 2 mm of
thrombus.
5. Reverse taper—dilation of the neck diameter 2 mm
within the first centimeter of the most caudal renal
artery. Patients with aortic necks 28 mm in diameter
(32 mm after 36-mm graft became available), lengths
10 mm, angulation 60°, 50% circumferential
thrombus, or with a reverse taper were defined as “hos-
tile.” Necks that lacked all of these criteria were defined
as “favorable.”
Surveillance imaging consisted of CT scans and aortic
ultrasound imaging performed at the discretion of the
attending physician. Follow-up imaging was obtained at 1-,
3-, 6-month, and 1-year intervals. If there were complica-
tions, the altered frequency of radiographic follow-up was
determined by the attending physician. The parameters
measured, as previously described,13,14 were proximal type
I endoleak, defined as evidence of perigraft contrast flow in
continuity with the proximal fixation site, and aneurysmal
sac enlargement, defined as an increase in the maximum
diameter of the aneurysmal sac 5 mm.
Demographics and procedural data. Data collected
included patient age at implantation, gender, and medical
comorbidities, including chronic obstructive pulmonary
disease (COPD), coronary artery disease, history of myo-
cardial infarction, history of cardiac arrhythmia, hyperten-
sion, end-stage renal disease (ESRD), history of stroke,
congestive heart failure (CHF), and smoking history. His-
tory of coronary artery bypass grafting (CABG) or percu-
taneous coronary intervention (PCI) was also obtained.
Baseline measurements of serum creatinine (mg/dL) were
documented. Hospital and intensive care unit lengths of
stay and 30-day mortality were recorded. Data recorded
during follow-up included the number of open surgical or
endovascular interventions, the number of hospital admis-
sions, and the postoperative length of stay. Vital status and
cause of death at the time of last known follow-up was
documented and verified with the Social Security Death
Index.
The decision to perform an EVAR was based on the
individual operator’s assessment of the clinical and ana-
tomic features in conjunction with detailed patient coun-
seling. Four commercially available stent grafts were used
during the study period: Excluder (W. L. Gore and Asso-
ciates, Scottsdale, Ariz), Zenith (Cook Inc, Bloomington,
Ind), and AneuRx and Talent (both Medtronic, Santa
Rosa, Calif). Two investigational devices were also used:
Aptus (Aptus Endosystems, Sunnyvale, Calif) and LeMaitre
(LeMaitre Vascular Inc, Burlington, Mass). The choice of
stent graft used was based on physician preference. The
aortic cuffs used were manufactured by W. L. Gore and
Associates or by Cook Inc. High pressure-balloon angio-
plasty was performed with the Z-Med balloon (B. Braun
Medical Inc, Bethlehem, Pa). The Palmaz stent was used
exclusively if a balloon expandable stent was required.Endograft placement was performed through bilateral
common femoral artery cutdowns, as described previously.
Postdeployment aortograms were performed routinely,
with adjunctive procedures performed as needed to treat
type I endoleaks or intraoperative device migration. Typi-
cally, high-pressure balloon angioplasty was initially at-
tempted. If that was unsuccessful, an aortic cuff was placed
if there was sufficient room. If an aortic cuff could not be
placed, or if a type I endoleak persisted, then a giant Palmaz
stent was deployed as described elsewhere.1,6,7,15,16 All
Palmaz stents were deployed using a 16F sheath and a
Z-med balloon.
Statistical analysis plan. Descriptive statistics were
used to describe demographic, anatomic, and hospital vari-
ables in mean  standard deviation. The primary outcome
variable was freedom from a GRE. Kaplan-Meier life table
analysis was used to assess rates of freedom from GRE and
is expressed as mean  standard error. Univariate analysis
was performed to evaluate the effect of all patient comor-
bidities, aneurysm anatomic variables, and intraoperative
factors on freedom from GRE. A multivariate Cox regres-
sion model was constructed using all univariate predictors
that were significant to a P .1 to evaluate for independent
predictors of GRE.
RESULTS
Baseline. From January 2005 through November
2007, 242 EVARS were performed at Emory University
Hospital, and 174 (72%) had preoperative CT scans avail-
able for analysis. Overall aneurysm diameter was 57.5 
11.2 mm, and 74 patients (43%) had hostile neck anatomy
(Table I). No significant differences in gender or comorbid
conditions were identified based on adjunctive procedure
status.
Outcomes. Mean patient follow-up was 15.2  12.2
months, with an estimated survival of 39  1 months (Fig
2). Approximately 50% of patients were lost to follow-up at
12 months. A device with infrarenal fixation only was used
in 74% of patients, and 25% received devices with suprare-
nal fixation. Data were missing for the type of endograft
that was placed for three patients (Table I).
Fifty-six patients (32%) underwent an adjunctive pro-
cedure during the initial EVAR: 22 had aortic cuff place-
ment alone, 15 had Palmaz stent placement alone, 12 had
aortic cuff and Palmaz stent placement, and 7 had high-
pressure balloon angioplasty alone. These were performed
for a type I endoleak in 49 patients (28%) and migration
alone in 7 (4%).
Forty-four devices with suprarenal fixation were placed,
and 6 (14%) of these required adjuncts (3 Palmaz stents and
3 aortic cuffs). One-hundred twenty devices with infrarenal
fixation were used, and 49 (41%) of these required ad-
juncts, comprising 12 Palmaz stents, 19 aortic cuffs, 12
Palmaz stent and aortic cuffs, and 6 high-pressure angio-
plasty procedures.
Three procedural type I endoleaks were managed with-
out adjunctive procedures at the time of primary EVAR.
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Freedom from graft-related events and predictors.
There were 14 deaths, 5 aortic sac enlargements, and 3
early type I endoleaks. Table II reports 30-day outcomes,
with no significant differences between the two groups with
respect to early endoleak rate, 30-day mortality, or early
reintervention rate. Univariate predictors of GRE-free sur-
vival included age, baseline creatinine, coronary artery dis-
ease, hostile neck anatomy, and Palmaz stent placement.
Among these, preoperative serum creatinine (hazard ratio,
1.39; P  .01) and age (hazard ratio, 1.08; P  .01)
remained significant in the multivariate model (Table III).
One particular subgroup that had an inferior Kaplan-
Meier estimated freedom from a GRE was the group that
received an adjunctive Palmaz stent (31.7  3.2 vs 39.6 
1.2 months; P  .04, log rank test). The higher event rate
in the Palmaz stent patients was secondary to a greater
Table 1. Demographic data, medical comorbidities,
aortic neck morphology, and type of device placed for
174 patients undergoing endovascular aneurysm repair
Variables
With adjunctive
proceduresa
(n  56)
No. (%) or
mean  SD
No adjunctive
proceduresa
(n  118)
No. (%) or
mean  SD
Age, year 73.5  9.4 71.8  8.3
Male 41 (73) 107 (90)
Aneurysm diameter, mm 58.9  12.1 56.8  10.7
Baseline SCr, mg/dL 1.57  1.7 1.17  0.4
Medical
COPD 13 (23) 27 (23)
Coronary artery disease 30 (55) 55 (46)
History of MI 14 (25) 19 (16)
History of CABG 19 (35) 31 (26)
History of PCI 9 (16) 23 (19)
Arrhythmia 8 (15) 10 (8)
ESRD 3 (5) 0 (0)
Congestive heart failure 7 (13) 6 (5)
Hypertension 35 (64) 78 (66)
History of stroke 6 (11) 6 (5)
Smoking 36 (65) 80 (68)
Current smoking 12 (22) 24 (20)
Aortic neck morphology
Proximal neck
Length, mm 16.2  10.5 21.9  10.4
Diameter, mm 24.9  3.7 24.4  3.7
Angulation, deg 45.0  22.7 37.2  20.6
Reverse taper 17 (31) 9 (16)
50% thrombus 5 (9) 5 (4)
Good 9 (16) 91 (77)
Hostile 47 (84) 27 (23)
Device fixation
Infrarenal 46 (87) 80 (67)
Suprarenal 6 (11) 38 (32)
CABG,Coronary artery bypass grafting;COPD, chronic obstructive pulmo-
nary disease; ESRD, end-stage renal disease (dialysis-dependent);MI, myo-
cardial infarction; PCI, percutaneous coronary intervention; SCr, serum
creatinine.
aThe P values for these variables were not statistically significant.number of sac enlargements relative to patients not receiv-ing Palmaz stents (5 vs 2). Patients receiving Palmaz stents
had the shortest necks (14.4  11.9 vs 20.7  9.8; P 
.004, 2) andmost severely angulated necks (52.5° 22.1°
vs 39.7°  19.8°; P  .003, 2). Ninety-six percent of the
Palmaz stents were placed in grafts lacking suprarenal fixa-
tion. The neck variables of reverse taper and thrombus were
not associated with Palmaz stent placement (P  NS, 2).
No medical comorbidity was associated with Palmaz stent
placement (P  NS, 2).
DISCUSSION
As expertise with EVAR grows, an increasing number
of interventionalists are treating patients with challenging
anatomy at the proximal neck of the aneurysm by using
adjunctive procedures during the initial EVAR. These ad-
juncts treat proximal endoleaks or migrations visible on the
completion angiogram. Although adjunctive techniques
often have a successful radiologic result with no evidence of
intraoperative endoleak, little is known about the long-
term efficacy of these adjunctive procedures. We present
the largest known series evaluating the midterm efficacy of
adjunctive procedures during the initial EVAR procedure.
Our series shows no significant difference in durability
between EVARs requiring adjuncts and those not requiring
adjuncts. Our approach is to offer open repair when appro-
priate, but patient preference and medical comorbidities
often result in the use of EVAR outside of the indications
for use (IFU).
The actuarial estimated survival of patients is short,
which reflects that our population was high-risk. Our pa-
tients did have a heightened risk profile relative to the
Medicare population as whole, with higher rates of renal
failure and coronary artery disease. The increased propor-
tion of high-risk characteristics is most likely due to referral
bias, which is becomingmore prevalent in similar case series
from high-volume tertiary referral centers.3 The appropri-
ateness of endograft placement in high-risk patients with
adjunctive neck therapies is an intriguing question due to
the increased prevalence of hostile aortic neck anatomy at
tertiary referral centers.3 To properly address this question
requires a control arm and is beyond the scope of this study.
The ability to use adjunctive neck procedures has per-
mitted our operators to obtain proximal fixation and seal
for aortic aneurysms in patients who are otherwise not
candidates for EVAR. If we encounter a type I endoleak on
completion arteriogram, we generally then sequentially
perform high-pressure balloon aortoplasty, followed by an
aortic cuff if that fails. The aortic cuffs are intended to
obtain amore proximal seal, while also providing additional
radial force. If there is still a type I endoleak, then our group
has used Palmaz stent placement.
Our findings extend those of Choke et al,1 who also
found that aortic aneurysms with severely angulated and
short necks could be safely managed with adjunctive pro-
cedures with comparable 30-day results to aortas with
favorable neck anatomy. Other smaller series5-9,16 also
suggested that EVAR could safely be broadened to patients
beyond the prior boundaries of hostile neck anatomy.
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follow-up. They did not address the issue of durability of
adjunctive procedures. The present series shows that pa-
tients can enjoy similar freedom from EVAR-related com-
plications regardless of whether adjunctive proximal neck
procedures were required. Although longer follow-up with
Fig 2. Kaplan-Meier (KM) freedom from graft-relate
repair.larger data sets is still required, our results suggest that thepresent IFU for EVARs aremost useful as guidelines.When
patient comorbidities and aortic morphology require ex-
ceptions to the IFU, adjunctive neck therapies can be used
with reasonable safety and efficacy tomanage complications
encountered at the proximal aortic neck.
The strongest predictors of event-free survival in our
nts is shown in patients with and without adjunctived eveseries were preoperative serum creatinine and age, most
JOURNAL OF VASCULAR SURGERY
December 20101440 Chung et allikely because death in the postoperative period was the
most frequent event. Using the Social Security Death Index
does not allow us to determine the cause of death, thus
there is no way to know whether the death was aneurysm-
related. These data are similar to those from the Lifeline
registry, the Dutch Randomised Endovascular Aneurysm
Management (DREAM) study, and the EVAR trial, show-
ing that overall mortality is not significantly altered by
aneurysm treatment.17-20 Palmaz stent placement and ad-
verse neck morphology are also markers for poor event-free
survival. Other univariate predictors such as coronary artery
disease and hostile neck morphology demonstrated colin-
earity with age and serum creatinine.
The use of aortic cuffs at the proximal neck did not
result in an increased GRE. Palmaz stent placement was
related tomore frequent GRE (increase in the aneurysm sac
size) in a univariate analysis but not in a multivariate model.
Palmaz stent placement at the proximal neck has been used
by our institution and others to abolish type I endoleaks
seen intraoperatively.1,5-7 However, too few cases were
performed with Palmaz stents in previous studies and
follow-up was insufficient to ascertain the durability of
Palmaz stent placement. Our findings suggest that EVARs
performed in conjunction with Palmaz stents may have
more graft-related events. Palmaz stents were used in the
shortest and most severely angulated necks, consistent with
the idea that Palmaz stents can help to lessen the aortic neck
angle and improve the seal between the fabric and aortic
wall by increasing the radial force.
The reasons for compromised midterm results with
Table II. Outcomes of 174 endovascular aneurysm
repairs
Variable
With adjunctive
procedures
(n  56)
No. (%)
No adjunctive
procedures
(n  118)
No. (%)
Procedural
Intra-op migration 5 mm 8 (14) 0 (0)
Intra-op type I endoleak 48 (86) 1 (1)
Primary-assisted success 54 (96) 117 (99)
30-day postprocedural
Type I endoleak 30 days 2 (4) 0 (0)
Secondary interventions 1 (2) 1 (1)
30-day mortality 1 (2) 0 (0)
Table III. Results of multivariate Cox regression analysis
Variable HR (95% CI) P
Baseline serum creatinine 1.39 (1.10-1.75) .01
Age 1.08 (1.02-1.15) .01
Coronary artery disease 0.45 (0.18-1.16) .10
Palmaz stent placement 1.80 (0.58-5.58) .31
Hostile neck 1.52 (0.49-4.68) .47
CI, Confidence interval; HR, hazard ratio.Palmaz placement remain unclear. It is possible that thePalmaz stent has inadequate radial force and is unable to
compensate for excessive angulation or provide enough
radial force to create a seal in short necks. Resultant en-
doleaks are small and undetected on the completion aorto-
gram and ultimately result in aortic sac enlargement. Alter-
natively, it is possible that the Palmaz stent has excessive
radial force that distorts the proximal aortic neck and causes
type I endoleaks and sac enlargement. Moreover as several
authors have observed, if initial sac exclusion is achieved,
aortic neck remodeling may ensue after endograft place-
ment,5,21 resulting in aortic neck enlargement, shortening,
and increased angulation that ultimately exceed the design
limitations of the endovascular therapies initially used to
obtain proximal fixation and seal. Most likely, however, is
that Palmaz stent placement is a marker for patients who
have the poorest survivorship and with aneurysms least
amenable to EVAR.
Multivariate modeling shows that Palmaz stent place-
ment did not independently predict GRE events; however,
the current study is one of the few series in the literature
that describes midterm results with its use. Presently, no
other device exists to provide additional radial force while
straightening the aortic neck. Because there is no compar-
ison arm, the appropriateness of Palmaz stent placement is
unclear; however, when unforeseen type I endoleaks are
encountered, Palmaz stent placement seems preferable to
open surgical conversion when no other alternative exists.
The main limitation of our study is inadequate statisti-
cal power. Based on a post hoc analysis, our power to detect
a difference in GRE between groups based on use of
adjuncts at the proximal neck was 80%. Thus, we cannot
exclude  error as a possible explanation for our results. The
number of patients lost to follow-up was high, especially
with respect to the collection of events such as late type I
endoleaks. We suspect that many tertiary care centers in the
United States struggle with this issue. Patients are eager to
travel far distances to receive their surgical treatment, but
become increasingly reluctant to return for follow-up. This
is particularly true when the initial imaging studies after the
EVAR show good results. Much of the data, moreover, was
collected retrospectively to augment the pre-existing data-
base, further limiting data collection. Further follow-up
and accrual of patients from multiple institutions may help
to ascertain whether there are other predictors of poor
outcome after EVARs.
CONCLUSIONS
Our results represent the largest single-center series
showing that difficult proximal aortic neck anatomy can be
successfully managed using endovascular adjunctive tech-
niques, with durable results at 1 year. Outcomes in elderly
patients with elevated baseline serum creatinine levels and
multiple comorbidities require further investigation to op-
timize risk-stratification and patient selection. Palmaz stent
placement requires close follow-up and is a marker for a less
durable repair. Further follow-up and comparisons with
other management strategies for hostile necks will be re-
quired to determine the optimal role for EVAR.
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